keyword
MENU ▼
Read by QxMD icon Read
search

Leukopenia

keyword
https://www.readbyqxmd.com/read/27910754/assessment-of-the-safety-of-the-shiitake-culinary-medicinal-mushroom-lentinus-edodes-agaricomycetes-in-rats-biochemical-hematological-and-antioxidative-parameters
#1
Denise Grotto, Daiane Cristovam Rosa Bueno, Gabriela Karine de Almeida Ramos, Susi Rosa da Costa, Sara Rosicler Vieira Spim, Marli Gerenutti
Lentinus edodes is an edible mushroom studied for use, or as an adjunct, in the prevention of illnesses such as hypertension, hypercholesterolemia, diabetes, and cancer. Despite the functional properties of L. edodes, the doses commonly reported in experimental studies are much higher than those actually consumed. Thus, we aimed to establish the optimum intake levels of L. edodes in vivo. Four groups of male Wistar rats received dry and powdered L. edodes reconstituted in water for 30 days: control (water only), L...
2016: International Journal of Medicinal Mushrooms
https://www.readbyqxmd.com/read/27908980/phase-2-study-of-eribulin-in-patients-with-previously-treated-advanced-or-metastatic-soft-tissue-sarcoma
#2
Akira Kawai, Nobuhito Araki, Yoichi Naito, Toshifumi Ozaki, Hideshi Sugiura, Yasuo Yazawa, Hideo Morioka, Akihiko Matsumine, Kenichi Saito, Shun Asami, Kazuo Isu
OBJECTIVE: Eribulin, a microtubule dynamics inhibitor, is approved for the treatment of patients with breast cancer and soft tissue sarcoma. We investigated the efficacy and safety of eribulin in Japanese patients with soft tissue sarcoma. METHODS: This open-label, multicenter, nonrandomized, Phase 2 study enrolled Japanese patients with measurable, advanced/metastatic soft tissue sarcoma of high/intermediate grade and ≥1 prior chemotherapy for advanced disease...
December 1, 2016: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27906684/phase-i-study-of-the-gamma-secretase-inhibitor-pf-03084014-in-combination-with-docetaxel-in-patients-with-advanced-triple-negative-breast-cancer
#3
Marzia A Locatelli, Philippe Aftimos, E Claire Dees, Patricia M LoRusso, Mark D Pegram, Ahmad Awada, Bo Huang, Rossano Cesari, Yuqiu Jiang, M Naveed Shaik, Kenneth A Kern, Giuseppe Curigliano
BACKGROUND: The NOTCH signaling pathway may be involved in the survival of stem cell-like tumor-initiating cells and contribute to tumor growth. In this phase Ib, open-label, multicenter study (NCT01876251), we evaluated PF-03084014, a selective gamma-secretase inhibitor in patients with advanced triple-negative breast cancer. METHODS: The dose-finding part was based on a 2×3 matrix design using the modified toxicity probability interval method. Oral PF-03084014 was administered twice daily continuously in combination with intravenous docetaxel given on day 1 of each 21-day cycle...
November 30, 2016: Oncotarget
https://www.readbyqxmd.com/read/27902478/a-retrospective-clinical-study-of-comparing-paclitaxel-plus-s-1-versus-paclitaxel-plus-cisplatin-as-the-first-line-treatment-for-patients-with-advanced-esophageal-squamous-cell-carcinoma
#4
Hai-Ying Wang, Zhi-Hua Yao, Hong Tang, Yan Zhao, Shui-Ling Jin, Wen-Ping Zhou, Shu-Na Yao, Shu-Jun Yang, Yan-Yan Liu, Su-Xia Luo
BACKGROUND: In advanced esophageal squamous cell carcinoma (ESCC), paclitaxel plus cisplatin are considered as active and tolerable. The current clinical study was conducted to retrospectively compare the efficacy and safety of first-line paclitaxel/S-1(PS) and paclitaxel/cisplatin(TP) regimens in advanced ESCC. RESULTS: The overall response rate of PS was slightly, but not significantly, higher (25 patients, 46%) than that of TP (23 patients, 39%, P = 0.432). Median overall survival (OS) was similar for PS and TP (11...
November 25, 2016: Oncotarget
https://www.readbyqxmd.com/read/27900638/bendamustine-plus-rituximab-for-previously-untreated-patients-with-indolent-b-cell-non-hodgkin-lymphoma-or-mantle-cell-lymphoma-a-multicenter-phase-ii-clinical-trial-in-japan
#5
Michinori Ogura, Kenichi Ishizawa, Dai Maruyama, Naokuni Uike, Kiyoshi Ando, Koji Izutsu, Yasuhito Terui, Yoshitaka Imaizumi, Kunihiro Tsukasaki, Kenshi Suzuki, Tohru Izumi, Kensuke Usuki, Tomohiro Kinoshita, Masafumi Taniwaki, Nobuhiko Uoshima, Junji Suzumiya, Mitsutoshi Kurosawa, Hirokazu Nagai, Toshiki Uchida, Noriko Fukuhara, Ilseung Choi, Ken Ohmachi, Go Yamamoto, Kensei Tobinai
A Phase II, multicenter clinical trial of bendamustine plus rituximab (BR) regimen was conducted in previously untreated patients with high-tumor-burden indolent B-cell non-Hodgkin lymphoma (B-NHL) and previously untreated elderly patients with mantle cell lymphoma (MCL) in Japan. Bendamustine 90 mg/m(2)/day on days 1 and 2, as well as rituximab 375 mg/m(2) on day 1 were administered intravenously up to six cycles. The primary endpoint was the complete response (CR) rate as assessed by the International Workshop Response Criteria (1999)...
November 29, 2016: International Journal of Hematology
https://www.readbyqxmd.com/read/27896440/a-phase-iii-open-label-randomized-multicenter-controlled-trial-of-oral-versus-intravenous-treosulfan-in-heavily-pretreated-recurrent-ovarian-cancer-a-study-of-the-north-eastern-german-society-of-gynecological-oncology-noggo
#6
Jalid Sehouli, Oliver Tomè, Desislava Dimitrova, Oumar Camara, Ingo Bernhard Runnebaum, Hans Werner Tessen, Beate Rautenberg, Radoslav Chekerov, Mustafa Zelal Muallem, Michael Patrick Lux, Tanja Trarbach, Gerald Gitsch
OBJECTIVE: In recurrent ovarian cancer (ROC), there is a high demand on effective therapies with a mild toxicity profile. Treosulfan is an alkylating agent approved as oral (p.o.) and intravenous (i.v.) formulation for the treatment of recurrent ovarian cancer. Data on safety and efficacy for either formulation are rare. For the first time we conducted a randomized phase III study comparing both formulations in women with ROC. METHODS: Patients having received at least two previous lines of chemotherapy were randomly assigned to one of two treatment arms: treosulfan i...
November 28, 2016: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/27888705/chemotherapy-related-leukopenia-as-a-biomarker-predicting-survival-outcomes-in-locally-advanced-cervical-cancer
#7
Giorgio Bogani, Ilaria Sabatucci, Giuseppa Maltese, Francesca Lecce, Mauro Signorelli, Fabio Martinelli, Valentina Chiappa, Alice Indini, Umberto Leone Roberti Maggiore, Chiara Borghi, Giovanni Fucà, Antonino Ditto, Francesco Raspagliesi, Domenica Lorusso
OBJECTIVE: To investigate the impact of hematologic toxicity and leukopenia in locally advanced cervical cancer patients undergoing neoadjuvant chemotherapy (NACT). STUDY DESIGN: Data of consecutive patients undergoing platinum-based NACT followed by surgery were retrospectively searched in order to evaluate the impact of chemotherapy-related toxicity on survival outcomes. Toxicity was graded per the Common Terminology Criteria for Adverse Events (CTCAEv.4.03). Survival outcomes were evaluated using Kaplan-Meir and Cox hazard models...
November 19, 2016: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/27888093/randomized-trial-of-ratg-daclizumab-vs-ratg-alemtuzumab-as-dual-induction-therapy-in-renal-transplantation-results-at-8-years-of-follow-up
#8
Gaetano Ciancio, Jeffrey J Gaynor, Giselle Guerra, Junichiro Sageshima, David Roth, Linda Chen, Warren Kupin, Adela Mattiazzi, Lissett Tueros, Sandra Flores, Lois Hanson, Phillip Ruiz, Rodrigo Vianna, George W Burke
Our goal in using dual induction therapy is to bring the kidney transplant recipient closer (through more effectively timed lymphodepletion) to an optimally immunosuppressed state. Here, we report long-term results of a prospective randomized trial comparing (Group I,N=100) rATG/Dac (3 rATG, 2 Dac doses) vs. (Group II,N=100) rATG/Alemtuzumab(C1H) (1 dose each), using reduced tacrolimus dosing, EC-MPS, and early corticosteroid withdrawal. Lower EC-MPS dosing was targeted in Group II to avoid severe leukopenia...
November 22, 2016: Transplant Immunology
https://www.readbyqxmd.com/read/27883280/phase-i-study-of-irinotecan-for-previously-treated-lung-cancer-patients-with-the-ugt1a1-28-or-6-polymorphism-results-of-the-lung-oncology-group-in-kyushu-logik1004a
#9
Minoru Fukuda, Midori Shimada, Takeshi Kitazaki, Seiji Nagashima, Kohji Hashiguchi, Noriyuki Ebi, Koichi Takayama, Yoichi Nakanishi, Hiroshi Semba, Taishi Harada, Takashi Seto, Isamu Okamoto, Yukito Ichinose, Kenji Sugio
BACKGROUND: Various polymorphisms have been detected in the UDP-glucuronosyltransferase 1A ( UGT1A ) gene, and UGT1A1 *28 and UGT1A1 *6 have important effects on the pharmacokinetics of irinotecan and the risk of severe toxicities during irinotecan therapy. This study was conducted to determine the maximum tolerated dose (MTD) of irinotecan chemotherapy according to the UGT1A1 genotype in previously treated lung cancer patients with the UGT1A1 *28 or UGT1A1 *6 polymorphism. METHODS: The eligibility criteria were as follows: lung cancer patients that had previously been treated with anticancer agents other than irinotecan, possessed the UGT1A1 *28 or UGT1A1 *6 polymorphism (group A included *28/*28, *6/*6, and *28/*6, and group B included *28 /- and *6 /-), were aged ≤75 years old, had a performance score of 0-1, and exhibited adequate bone marrow function...
November 24, 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27881648/modeling-severe-fever-with-thrombocytopenia-syndrome-virus-infection-in-golden-syrian-hamsters-importance-of-stat2-in-preventing-disease-and-effective-treatment-with-favipiravir
#10
Brian B Gowen, Jonna B Westover, Jinxin Miao, Arnaud J Van Wettere, Johanna D Rigas, Brady T Hickerson, Kie-Hoon Jung, Rong Li, Bettina L Conrad, Skot Nielson, Yousuke Furuta, Zhongde Wang
: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne disease endemic in parts of Asia. The etiologic agent, SFTS virus (SFTSV; Bunyaviridae family, Phlebovirus genus) has caused significant morbidity and mortality in China, Korea, and Japan, with key features of disease being intense fever, thrombocytopenia, and leukopenia. Case fatality rates are estimated in the 30% range and no antivirals or vaccines are approved for use for treatment and prevention of SFTS...
November 23, 2016: Journal of Virology
https://www.readbyqxmd.com/read/27879260/antibiotics-impair-murine-hematopoiesis-by-depleting-intestinal-microbiota
#11
Kamilla S Josefsdottir, Megan T Baldridge, Claudine S Kadmon, Katherine Y King
Bone marrow suppression is an adverse effect associated with many antibiotics, especially when administered for prolonged treatment courses. Recent advances in our understanding of steady-state hematopoiesis have allowed us to explore the effects of antibiotics on hematopoietic progenitors in detail using a murine model. Antibiotic-treated mice exhibited anemia, thrombocytosis, and leukopenia, with pronounced pan-lymphopenia as demonstrated by flow cytometric analysis of peripheral blood. Bone marrow progenitor analysis revealed depletion of hematopoietic stem cells and multipotent progenitors across all subtypes...
November 22, 2016: Blood
https://www.readbyqxmd.com/read/27878356/phase-i-trial-of-daily-triapine-in-combination-with-cisplatin-chemotherapy-for-advanced-stage-malignancies
#12
Charles A Kunos, Edward Chu, Jan H Beumer, Mario Sznol, S Percy Ivy
PURPOSE: Advanced-stage malignancies have increased deoxyribonucleotide demands in DNA replication and repair, making deoxyribonucleotide supply a potential exploitable target for therapy based on ribonucleotide reductase (RNR) inhibition. METHODS: A dose-finding phase I trial was conducted of intravenous (i.v.) triapine, a small-molecule RNR inhibitor, and cisplatin chemotherapy in patients with advanced-stage solid tumor malignancies. Patients received dose-finding levels of i...
November 22, 2016: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/27874969/idiopathic-myelofibrosis-accompanied-by-peritoneal-extramedullary-hematopoiesis-presenting-as-refractory-ascites-in-a-dog
#13
Yolandi Rautenbach, Amelia Goddard, Sarah J Clift
A 2.5-year-old spayed female American Pit Bull Terrier dog presented with a primary complaint of chronic refractory ascites. The dog's CBC displayed a moderate to severe macrocytic, hypochromic, nonregenerative anemia, and a moderate leukopenia as result of a moderate neutropenia and monocytopenia. Microscopic examination of the blood smear showed marked anisocytosis, mild polychromasia, mild acanthocytosis and ovalocytosis, moderate schistocytosis and poikilocytosis, and 4 metarubricytes/100 WBC. Abdominal ultrasonography revealed a homogenous, mild to moderately hyperechoic appearing liver as well as marked amounts of speckled anechoic to slightly hypoechoic peritoneal fluid...
November 22, 2016: Veterinary Clinical Pathology
https://www.readbyqxmd.com/read/27870069/suspected-myelodysplastic-myeloproliferative-neoplasm-in-a-feline-leukemia-virus-negative-cat
#14
Amy L Weeden, Kyle R Taylor, Scott P Terrell, Alexander E Gallagher, Heather L Wamsley
A 10-year-old castrated Domestic Short-Haired cat was presented to a primary care veterinarian for a wellness examination and laboratory examination for monitoring of diabetes mellitus. The CBC revealed marked thrombocytosis, leukopenia and macrocytic, normochromic anemia. The cat tested negative for FeLV and feline immunodeficiency virus, but was positive for Mycoplasma haemominutum by PCR. Hematologic abnormalities were not responsive to therapy, so a repeat CBC and a bone marrow aspiration for cytology were performed...
November 21, 2016: Veterinary Clinical Pathology
https://www.readbyqxmd.com/read/27869591/vertebrate-host-susceptibility-to-heartland-virus
#15
Angela M Bosco-Lauth, Amanda E Calvert, J Jeffrey Root, Tom Gidlewski, Brian H Bird, Richard A Bowen, Atis Muehlenbachs, Sherif R Zaki, Aaron C Brault
Heartland virus (HRTV) is a recently described phlebovirus initially isolated in 2009 from 2 humans who had leukopenia and thrombocytopenia. Serologic assessment of domestic and wild animal populations near the residence of 1 of these persons showed high exposure rates to raccoons, white-tailed deer, and horses. To our knowledge, no laboratory-based assessments of viremic potential of animals infected with HRTV have been performed. We experimentally inoculated several vertebrates (raccoons, goats, chickens, rabbits, hamsters, C57BL/6 mice, and interferon-α/β/γ receptor-deficient [Ag129]) mice with this virus...
December 2016: Emerging Infectious Diseases
https://www.readbyqxmd.com/read/27866577/novel-developments-in-leukopenia-and-pancytopenia
#16
REVIEW
Chisom Onuoha, Junaid Arshad, John Astle, Mina Xu, Stephanie Halene
Cytopenias are not disease entities in and of themselves; rather, they are the expression of various underlying disease processes. Careful attention to details in patients' presentation, careful history and examination, as well as attention to the ancillary parameters of the complete blood count with a peripheral blood smear can point the clinician toward the appropriate workup. Causes of cytopenias can be inherited or acquired; the latter include medication related, autoimmune, or neoplastic causes. Emergencies need to be recognized in a timely fashion and expert consultation obtained...
December 2016: Primary Care
https://www.readbyqxmd.com/read/27858891/pediatric-visceral-leishmaniasis-in-northwest-of-iran
#17
Babak Abdinia, Mohammad Oliaei-Motlagh, Amir Teimouri-Dereshki
Leishmaniasis is one of the major health problems in Iran. Although the incidence of visceral leishmaniasis (VL) is reported almost everywhere, the northwestern Iran is one of the major endemic regions.To do this study, clinical, laboratory as well as disease characteristics of children admitted to Children Cure and Health Hospital, Tabriz University of Medical Sciences, were examined as the reference hospital for the treatment of VL in northwestern Iran.In this study, 156 children hospitalized in a pediatric hospital from 2000 to 2015 for VL were included...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27852063/depression-induces-poor-prognosis-associates-with-the-down-regulation-brain-derived-neurotrophic-factor-of-serum-in-advanced-small-cell-lung-cancer
#18
Yufeng Wu, Ruirui Si, Sen Yang, Suhua Xia, Zelai He, Lili Wang, Zhen He, Qiming Wang, Hong Tang
Patients with lung cancer often experience a state of depression, and these conditions may severely affect their quality of life (QoL) and prescription compliance. The current study was conducted to delineate the complex links between depression and the prognosis of patients with small cell lung cancer (SCLC) and the underlying mechanism was also explored.186 patients who received platinum-based chemotherapy for newly diagnosed stage III or stage IV SCLC were enrolled. The Self-Rating Depression Scale (SDS) questionnaire was completed the day before the start of chemotherapy to assess the depression status of the patients...
November 11, 2016: Oncotarget
https://www.readbyqxmd.com/read/27851998/clinical-and-molecular-features-of-adenovirus-type-2-3-and-7-infections-in-children-in-an-outbreak-in-taiwan-2011
#19
Ming-Ru Lin, Shu-Li Yang, Yu-Nong Gong, Ching-Chia Kuo, Cheng-Hsun Chiu, Chih-Jung Chen, Yu-Chia Hsieh, Chen-Yen Kuo, Chun-Wan Fang, Kuo-Chien Tsao, Yhu-Chering Huang
OBJECTIVES: We studied pediatric patients with human adenovirus (HAdV) infection during the 2011 outbreak in northern Taiwan in order to define the clinical features of different HAdV genotypes in children. METHODS: Between January and December 2011, 637 patients <19 years of age exhibited culture-confirmed adenoviral infection in Chang Gung Memorial Hospital, and provided specimens available for genotyping by multiplex real-time polymerase chain reaction. Clinical data were retrospectively collected...
November 13, 2016: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/27848182/elotuzumab-with-lenalidomide-and-dexamethasone-for-japanese-patients-with-relapsed-refractory-multiple-myeloma-phase-1-study
#20
Shinsuke Iida, Hirokazu Nagai, Gen Kinoshita, Masafumi Miyoshi, Michael Robbins, Dimple Pandya, Eric Bleickardt, Takaaki Chou
Elotuzumab is an immunostimulatory monoclonal antibody that binds to SLAMF7, a type-1 transmembrane protein expressed on myeloma and natural killer cells. We report a phase 1 study (NCT01241292) in which we evaluated the safety, efficacy and pharmacokinetics of elotuzumab combined with lenalidomide and dexamethasone in Japanese patients with relapsed/refractory multiple myeloma (RRMM). In 28-day cycles, patients received: elotuzumab (intravenously), lenalidomide (25 mg orally) and weekly dexamethasone (elotuzumab days: 28 mg orally plus 8 mg intravenously; non-elotuzumab days: 40 mg orally)...
November 15, 2016: International Journal of Hematology
keyword
keyword
18500
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"